Partnership and licensing opportunities from Progenity.
Current therapeutics offer poor efficacy in many IBD cases. GI tract inflammation and lesions contribute to this poor efficacy by accelerating drug loss into the GI tract. Achieving higher drug concentrations in the diseased tissues may lead to improved drug response and remission rates in patients suffering from IBD.
Progenity’s targeted delivery platform offers the ability to accurately localize and deliver drugs at the site of disease in the GI tract. This will enable the necessary therapeutic tissue dose, improving efficacy while limiting systemic exposure and side effects. Candidate drugs for this form of delivery are those that predominantly act in the intestinal tissues, but currently have limited efficacy because of systemic toxicities. With lower systemic absorption, the technology is likely ideal for use in combination therapies to increase efficacy without increasing adverse effects.
This is the Partnership and Licensing section of the company profile page for Progenity on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.